Roche pays Repare $125M to join Big Pharma peers in cancer racenews2022-06-02T08:35:40+00:00June 2nd, 2022|FierceBiotech|
Merck KGaA nabs another baton in protein degradation race with $554M Proxygen dealnews2022-06-02T03:45:16+00:00June 2nd, 2022|FierceBiotech|
Oncology trial starts hit record levels as COVID disruptions ease: reportnews2022-06-02T00:58:17+00:00June 2nd, 2022|FierceBiotech|
Samantha Truex did a rare thing last time she was CEO: admit defeat. She’s back with a new biotech and $200Mnews2022-06-01T20:57:44+00:00June 1st, 2022|FierceBiotech|
From Big Pharma to little Tessera, Michael Severino rewrites his next chapter as CEO of Flagship biotechnews2022-06-01T16:37:33+00:00June 1st, 2022|FierceBiotech|
Amgen’s heart drug reduces cardiovascular disease risk factor in phase 2 trialnews2022-06-01T15:02:06+00:00June 1st, 2022|FierceBiotech|
Tech-Enabled Trials Don’t Have to Mean Loss of Human Connectionnews2022-06-01T15:00:52+00:00June 1st, 2022|FierceBiotech|
BioMarin’s hemophilia A gene therapy further delayed amid new FDA questionsnews2022-06-01T14:06:44+00:00June 1st, 2022|FierceBiotech|
Sanofi’s Hemlibra rival gets step closer to approval with FDA breakthrough tagnews2022-06-01T13:55:05+00:00June 1st, 2022|FierceBiotech|
SKYLARK sings: Sage, Biogen hatch positive phase 3 data in postpartum depressionnews2022-06-01T11:39:08+00:00June 1st, 2022|FierceBiotech|
